vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Dine Brands Global, Inc. (DIN). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $217.6M, roughly 1.3× Dine Brands Global, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -5.6%, a 102.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 6.3%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 2.7%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Dine Brands Global Inc. is a publicly traded food and beverage company based in Pasadena, California. Founded in 1958 as IHOP, it operates franchised and corporate owned full-service restaurants including three restaurant concepts, Applebee's Neighborhood Grill & Bar, International House of Pancakes (IHOP), and Fuzzy's Taco Shop.
ACAD vs DIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $217.6M |
| Net Profit | $273.6M | $-12.2M |
| Gross Margin | 90.8% | 42.4% |
| Operating Margin | 6.1% | -7.6% |
| Net Margin | 96.3% | -5.6% |
| Revenue YoY | 9.4% | 6.3% |
| Net Profit YoY | 90.3% | -336.1% |
| EPS (diluted) | $1.61 | $-0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $217.6M | ||
| Q3 25 | $278.6M | $216.2M | ||
| Q2 25 | $264.6M | $230.8M | ||
| Q1 25 | $244.3M | $214.8M | ||
| Q4 24 | $259.6M | $204.8M | ||
| Q3 24 | $250.4M | $195.0M | ||
| Q2 24 | $242.0M | $206.3M | ||
| Q1 24 | $205.8M | $206.2M |
| Q4 25 | $273.6M | $-12.2M | ||
| Q3 25 | $71.8M | $7.3M | ||
| Q2 25 | $26.7M | $13.8M | ||
| Q1 25 | $19.0M | $8.2M | ||
| Q4 24 | $143.7M | $5.2M | ||
| Q3 24 | $32.8M | $19.1M | ||
| Q2 24 | $33.4M | $23.2M | ||
| Q1 24 | $16.6M | $17.5M |
| Q4 25 | 90.8% | 42.4% | ||
| Q3 25 | 92.2% | 39.1% | ||
| Q2 25 | 92.2% | 40.0% | ||
| Q1 25 | 91.7% | 42.0% | ||
| Q4 24 | 91.6% | 41.7% | ||
| Q3 24 | 92.5% | 47.8% | ||
| Q2 24 | 92.5% | 48.1% | ||
| Q1 24 | 88.8% | 47.2% |
| Q4 25 | 6.1% | -7.6% | ||
| Q3 25 | 12.8% | 4.7% | ||
| Q2 25 | 12.2% | 8.2% | ||
| Q1 25 | 7.9% | 6.0% | ||
| Q4 24 | 59.1% | 3.8% | ||
| Q3 24 | 12.6% | 13.6% | ||
| Q2 24 | 12.6% | 15.1% | ||
| Q1 24 | 7.4% | 11.7% |
| Q4 25 | 96.3% | -5.6% | ||
| Q3 25 | 25.8% | 3.4% | ||
| Q2 25 | 10.1% | 6.0% | ||
| Q1 25 | 7.8% | 3.8% | ||
| Q4 24 | 55.4% | 2.5% | ||
| Q3 24 | 13.1% | 9.8% | ||
| Q2 24 | 13.8% | 11.2% | ||
| Q1 24 | 8.0% | 8.5% |
| Q4 25 | $1.61 | $-0.79 | ||
| Q3 25 | $0.42 | $0.48 | ||
| Q2 25 | $0.16 | $0.89 | ||
| Q1 25 | $0.11 | $0.53 | ||
| Q4 24 | $0.86 | $0.35 | ||
| Q3 24 | $0.20 | $1.24 | ||
| Q2 24 | $0.20 | $1.50 | ||
| Q1 24 | $0.10 | $1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $128.2M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $1.2B | $-273.9M |
| Total Assets | $1.6B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $128.2M | ||
| Q3 25 | $258.0M | $167.9M | ||
| Q2 25 | $253.6M | $194.2M | ||
| Q1 25 | $217.7M | $186.5M | ||
| Q4 24 | $319.6M | $186.7M | ||
| Q3 24 | $155.1M | $169.6M | ||
| Q2 24 | $177.1M | $153.5M | ||
| Q1 24 | $204.7M | $145.0M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $1.2B | $-273.9M | ||
| Q3 25 | $917.3M | $-231.9M | ||
| Q2 25 | $822.4M | $-212.5M | ||
| Q1 25 | $765.2M | $-215.7M | ||
| Q4 24 | $732.8M | $-216.0M | ||
| Q3 24 | $577.2M | $-216.7M | ||
| Q2 24 | $516.7M | $-231.7M | ||
| Q1 24 | $464.0M | $-244.8M |
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.3B | $1.8B | ||
| Q2 25 | $1.2B | $1.8B | ||
| Q1 25 | $1.1B | $1.8B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $976.9M | $1.7B | ||
| Q2 24 | $914.1M | $1.7B | ||
| Q1 24 | $855.1M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $5.7M |
| Free Cash FlowOCF − Capex | — | $-8.6M |
| FCF MarginFCF / Revenue | — | -3.9% |
| Capex IntensityCapex / Revenue | — | 6.6% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $53.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $5.7M | ||
| Q3 25 | $74.3M | $30.2M | ||
| Q2 25 | $64.0M | $37.0M | ||
| Q1 25 | $20.3M | $16.1M | ||
| Q4 24 | $40.4M | $30.5M | ||
| Q3 24 | $63.2M | $25.5M | ||
| Q2 24 | $25.0M | $21.6M | ||
| Q1 24 | $29.1M | $30.6M |
| Q4 25 | — | $-8.6M | ||
| Q3 25 | $73.9M | $18.1M | ||
| Q2 25 | — | $31.0M | ||
| Q1 25 | — | $12.8M | ||
| Q4 24 | — | $26.7M | ||
| Q3 24 | $63.2M | $22.0M | ||
| Q2 24 | — | $18.2M | ||
| Q1 24 | — | $27.2M |
| Q4 25 | — | -3.9% | ||
| Q3 25 | 26.5% | 8.4% | ||
| Q2 25 | — | 13.4% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 25.2% | 11.3% | ||
| Q2 24 | — | 8.8% | ||
| Q1 24 | — | 13.2% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | 0.1% | 5.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | 0.0% | 1.8% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 4.12× | ||
| Q2 25 | 2.40× | 2.68× | ||
| Q1 25 | 1.07× | 1.97× | ||
| Q4 24 | 0.28× | 5.88× | ||
| Q3 24 | 1.93× | 1.34× | ||
| Q2 24 | 0.75× | 0.93× | ||
| Q1 24 | 1.76× | 1.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
DIN
| Franchisor | $163.2M | 75% |
| Food And Beverage | $27.3M | 13% |
| Proprietary Product Sales And Other | $17.0M | 8% |
| Other | $8.1M | 4% |
| Franchise And Development Fees | $2.0M | 1% |
